Form 4											
Check thi	s box	STATES			AND EXC , D.C. 205		GE C	OMMISSION	OMB AF OMB Number: Expires:	PROVAL 3235-0287 January 31,	
if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							e Act of 1934, 1935 or Section	Estimated a burden hou response			
(Print or Type R	Responses)										
Giaccia Amato S			2. Issuer Name and Ticker or Trading Symbol Aravive, Inc. [ARAV]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O ARAVI INC., LYON 1221 MCKI	IVE, IDELLBASEL 7	Middle) ΓOWER,	3. Date of (Month/D 10/12/20	-	ransaction			X Director	title Othe below)	Owner	
Filed(M				nendment, Date Original onth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
(City)	(State)	(Zip)						Person			
1.Title of Security (Instr. 3)	(State) 2. Transaction Dat (Month/Day/Year)	e 2A. Deen Execution any	ned n Date, if	3.	4. Securiti on(A) or Dis (Instr. 3, 4	es Acq posed o	uired of (D)	uired, Disposed of 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common Stock	10/12/2018			А	941,880	А	<u>(1)</u>	941,880	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Giaccia Amato - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day,	ate	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 0.06	10/12/2018		А	8,055	(2)	04/25/2021	Common Stock	8,055
Stock Option (Right to Buy)	\$ 0.06	10/12/2018		А	4,028	(3)	04/25/2021	Common Stock	4,028
Stock Option (Right to Buy)	\$ 0.06	10/12/2018		A	12,350	<u>(4)</u>	11/14/2022	Common Stock	12,350
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		А	38,761	(5)	09/30/2024	Common Stock	38,761
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		А	9,120	(6)	12/31/2024	Common Stock	9,120
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		А	9,120	(7)	03/31/2025	Common Stock	9,120
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		А	9,120	(8)	06/30/2025	Common Stock	9,120
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		А	26,813	<u>(9)</u>	06/30/2025	Common Stock	26,813
Stock Option (Right to Buy)	\$ 0.24	10/12/2018		A	9,120	<u>(10)</u>	09/30/2025	Common Stock	9,120

8 I S ()

Stock Option (Right to Buy)	\$ 0.24	10/12/2018	A	9,120	(11)	12/31/2025	Common Stock	9,120
Stock Option (Right to Buy)	\$ 0.24	10/12/2018	A	9,120	(12)	03/31/2026	Common Stock	9,120
Stock Option (Right to Buy)	\$ 0.66	10/12/2018	A	38,001	(13)	06/14/2027	Common Stock	38,001
Stock Option (Right to Buy)	\$ 0.9	10/12/2018	A	19,000	(14)	12/14/2027	Common Stock	19,000
Stock Option (RIght to Buy)	\$ 0.9	10/12/2018	A	19,000	(15)	03/20/2028	Common Stock	19,000

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Giaccia Amato C/O ARAVIVE, INC. LYONDELLBASEL TOWER, 1221 MCKINNEY ST. HOUSTON, TX 77010	Х	Х			
Signatures					

/s/ Kevin Haas,	10/16/2018
Attorney-in-fact	10/10/2018

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Shares of common stock of the corporation known as Aravive Biologics, Inc. ("Aravive") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and among the Issuer, Velo Merger Sub, Inc. and Aravive (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Aravive

- (1) common stock was exchanged for 2.2801 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every six shares of Issuer common stock outstanding and the Issuer changed its name to Aravive, Inc. All share and option numbers reflect the reverse stock split.
- (2) On April 26, 2011, Reporting Person was granted an option to purchase 21,199 shares of the common stock of Aravive at an exercise price of \$0.02 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 8,055 shares of Issuer

Edgar Filing: Giaccia Amato - Form 4

common stock (as adjusted for the stock split) at a per share exercise price of \$0.06 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On April 26, 2011, Reporting Person was granted an option to purchase 10,600 shares of the common stock of Aravive at an exercise price of \$0.02 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 4,028 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.06 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On November 14, 2012, Reporting Person was granted an option to purchase 32,500 shares of the common stock of Aravive at an exercise price of \$0.02 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 12,350 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.06 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On October 1, 2014, Reporting Person was granted an option to purchase 102,000 shares of the common stock of Aravive at an exercise price of \$0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 38,761 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On December 31, 2014, Reporting Person was granted an option to purchase 24,000 shares of the common stock of Aravive at an exercise price of \$0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,120 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On March 31, 2015, Reporting Person was granted an option to purchase 24,000 shares of the common stock of Aravive at an exercise price of \$0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,120 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

(8) On June 30, 2015, Reporting Person was granted an option to purchase 24,000 shares of the common stock of Aravive at an exercise price of \$0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,120 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On July 1, 2015, Reporting Person was granted an option to purchase 70,559 shares of the common stock of Aravive at an exercise price of \$0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 26,813 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On September 30, 2015, Reporting Person was granted an option to purchase 24,000 shares of the common stock of Aravive at an exercise price of \$0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,120 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On December 31, 2015, Reporting Person was granted an option to purchase 24,000 shares of the common stock of Aravive at an exercise price of \$0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,120 shares

(11) exercise price of \$0.09 per share. Pursuant to the Merger Agreenent, this option was converted into an option to purchase 9,120 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

(12) On March 31, 2016, Reporting Person was granted an option to purchase 24,000 shares of the common stock of Aravive at an exercise price of \$0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,120 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On June 15, 2017, Reporting Person was granted an option to purchase 100,000 shares of the common stock of Aravive at an exercise price of \$0.23 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 38,001 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.66 per share (as adjusted for the stock split). The option

is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On December 14, 2017, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Aravive at an exercise price of \$0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares

(14) exercise price of \$0.94 per share. I distant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

On March 20, 2018, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Aravive at an exercise price of \$0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares of Issuer

(15) price of \$0.54 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares of issuer common stock (as adjusted for the stock split) at a per share exercise price of \$0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

Edgar Filing: Giaccia Amato - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.